Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tropical Disease Development Partnerships Want More Help From FDA

Executive Summary

The agency’s infrastructure is not attracting many of the Product Development Partnership sponsors, Aeras official says, but new draft guidance could help.

You may also be interested in...



FDA Aims Neglected Tropical Disease Guidance At Inexperienced Sponsors

Big pharma is not the prime player in the tropical disease area, even as some large firms increase funding.

Increased FDA China Inspections Backed By House Panel, While Purse Strings Pulled Still Tighter

Funds for the Reagan-Udall Foundation must come from the FDA commissioner’s office account, under successful amendment from Rep. DeLauro.

TB Regimen Could Pave Way For More FDA Involvement In Neglected Tropical Diseases

TB Alliance plans to seek FDA approval for its treatment regimen, which is beginning a Phase IIb trial, as the agency looks to respond to calls for a clearer and quicker pathway for NTD drugs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel